Chemical: Drug
lamotrigine

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for lamotrigine

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA HLA-A *03:01:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-A *23:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-A *30:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-A *33:03:01 N/A N/A N/A
No VIP available No VIP available VA HLA-A *68:01:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *13:02:01 N/A N/A N/A
VIP CA VA HLA-B *15:02:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *40:02:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *44:03:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *57:01:01 N/A N/A N/A
No VIP available CA VA HLA-B *58:01 N/A N/A N/A
No VIP available No VIP available VA HLA-C *07:18 N/A N/A N/A
No VIP available No VIP available VA HLA-DQB1 *06:09 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *13:01:01 N/A N/A N/A
No VIP available CA VA UGT1A4 *1a N/A N/A N/A
No VIP available CA VA UGT1A4 *2 N/A N/A N/A
No VIP available No VIP available VA UGT1A4 *3a N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs10068980 NC_000005.10:g.161860841G>A, NC_000005.9:g.161287847G>A, NG_011548.1:g.18651G>A, NM_000806.5:c.188-4880G>A, NM_001127643.1:c.188-4880G>A, NM_001127644.1:c.188-4880G>A, NM_001127645.1:c.188-4880G>A, NM_001127648.1:c.188-4880G>A, rs61304955
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs1112122 NC_000023.10:g.151606004G>T, NC_000023.11:g.152437532G>T, NG_007102.1:g.18827C>A, NM_000808.3:c.-27+13614C>A, XM_005274659.1:c.-27+13614C>A, XM_005274660.1:c.-27+13614C>A, XM_006724811.1:c.-27+13614C>A, XM_011531133.1:c.-27+13614C>A, XM_011531134.1:c.-27+13614C>A, rs60180048
G > T
SNP
No VIP available No Clinical Annotations available VA
rs1128503 NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317
A > G
SNP
G412G
No VIP available No Clinical Annotations available VA
rs1157122 NC_000005.10:g.161892308T>C, NC_000005.9:g.161319314T>C, NG_011548.1:g.50118T>C, NM_000806.5:c.856+1258T>C, NM_001127643.1:c.856+1258T>C, NM_001127644.1:c.856+1258T>C, NM_001127645.1:c.856+1258T>C, NM_001127648.1:c.856+1258T>C, rs57694082
T > C
SNP
No VIP available CA VA
rs2011425 NC_000002.11:g.234627608T>G, NC_000002.12:g.233718962T>G, NG_002601.2:g.134219T>G, NM_001072.3:c.861+25097T>G, NM_007120.2:c.142T>G, NM_019075.2:c.856-48072T>G, NM_019076.4:c.856-48072T>G, NM_019077.2:c.855+36170T>G, NM_019078.1:c.867+5104T>G, NM_021027.2:c.855+46173T>G, NM_205862.1:c.60+25097T>G, NP_009051.1:p.Leu48Val, XR_241238.1:n.198T>G, XR_241240.1:n.1022+25097T>G, XR_241241.1:n.941+46173T>G, rs16849670, rs17866635, rs58554624
T > G
SNP
L48V
No VIP available CA VA
rs2071197 NC_000020.10:g.43030435G>A, NC_000020.11:g.44401795G>A, NG_009818.1:g.50995G>A, NM_000457.4:c.115+308G>A, NM_001030003.2:c.50-4263G>A, NM_001030004.2:c.50-4263G>A, NM_001258355.1:c.3+308G>A, NM_001287182.1:c.41-4263G>A, NM_001287183.1:c.41-4263G>A, NM_001287184.1:c.41-4263G>A, NM_175914.4:c.50-4263G>A, NM_178849.2:c.115+308G>A, NM_178850.2:c.115+308G>A, XM_005260407.1:c.141+282G>A, XM_005260407.2:c.141+282G>A, XM_011528797.1:c.-687G>A, XM_011528798.1:c.-687G>A, rs3212176, rs61166839
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2231137 NC_000004.11:g.89061114C>T, NC_000004.12:g.88139962C>T, NG_032067.2:g.96361G>A, NM_001257386.1:c.34G>A, NM_004827.2:c.34G>A, NP_001244315.1:p.Val12Met, NP_004818.2:p.Val12Met, XM_005263354.1:c.34G>A, XM_005263354.2:c.34G>A, XM_005263355.1:c.34G>A, XM_005263355.2:c.34G>A, XM_005263356.1:c.34G>A, XM_005263356.2:c.34G>A, XM_011532420.1:c.34G>A, XP_005263411.1:p.Val12Met, XP_005263412.1:p.Val12Met, XP_005263413.1:p.Val12Met, XP_011530722.1:p.Val12Met
C > T
SNP
V12M
No VIP available CA VA
rs2231142 NC_000004.11:g.89052323G>T, NC_000004.12:g.88131171G>T, NG_032067.2:g.105152C>A, NM_001257386.1:c.421C>A, NM_004827.2:c.421C>A, NP_001244315.1:p.Gln141Lys, NP_004818.2:p.Gln141Lys, XM_005263354.1:c.421C>A, XM_005263354.2:c.421C>A, XM_005263355.1:c.421C>A, XM_005263355.2:c.421C>A, XM_005263356.1:c.421C>A, XM_005263356.2:c.421C>A, XM_011532420.1:c.421C>A, XP_005263411.1:p.Gln141Lys, XP_005263412.1:p.Gln141Lys, XP_005263413.1:p.Gln141Lys, XP_011530722.1:p.Gln141Lys, rs12721641, rs28365035, rs3736117, rs52809243, rs58973676
G > T
SNP
Q141K
No VIP available No Clinical Annotations available VA
rs2273697 NC_000010.10:g.101563815G>A, NC_000010.11:g.99804058G>A, NG_011798.1:g.26353G>A, NM_000392.4:c.1249G>A, NP_000383.1:p.Val417Ile, XM_005269536.1:c.1249G>A, XM_006717630.2:c.553G>A, XM_006717631.2:c.1249G>A, XM_011539291.1:c.1249G>A, XP_005269593.1:p.Val417Ile, XP_006717693.1:p.Val185Ile, XP_006717694.1:p.Val417Ile, XP_011537593.1:p.Val417Ile, XR_945604.1:n.1438G>A, XR_945605.1:n.1440G>A, rs17216184, rs60620335
G > A
SNP
V417I
No VIP available No Clinical Annotations available VA
rs2282143 NC_000006.11:g.160557643C>T, NC_000006.12:g.160136611C>T, NM_003057.2:c.1022C>T, NM_153187.1:c.1022C>T, NP_003048.1:p.Pro341Leu, NP_694857.1:p.Pro341Leu, XM_005267102.1:c.1022C>T, XM_005267102.3:c.1022C>T, XM_005267103.1:c.1022C>T, XM_005267104.1:c.446C>T, XM_005267104.3:c.446C>T, XM_005267105.1:c.446C>T, XM_005267105.3:c.446C>T, XM_006715552.1:c.1022C>T, XM_011536074.1:c.446C>T, XP_005267159.1:p.Pro341Leu, XP_005267160.1:p.Pro341Leu, XP_005267161.1:p.Pro149Leu, XP_005267162.1:p.Pro149Leu, XP_006715615.1:p.Pro341Leu, XP_011534376.1:p.Pro149Leu, rs56860747
C > T
SNP
P341L
No VIP available CA VA
rs2304016 NC_000002.11:g.166168503A>G, NC_000002.12:g.165311993A>G, NG_008143.1:g.77592A>G, NM_001040142.1:c.971-32A>G, NM_001040143.1:c.971-32A>G, NM_021007.2:c.971-32A>G, XM_005246750.1:c.971-32A>G, XM_005246750.2:c.971-32A>G, XM_005246751.1:c.971-32A>G, XM_005246752.1:c.971-32A>G, XM_005246753.1:c.971-32A>G, XM_005246753.2:c.971-32A>G, XM_005246754.1:c.941-32A>G, XM_005246754.3:c.941-32A>G, XM_005246755.1:c.218-32A>G, XM_005246755.3:c.218-32A>G, XM_011511608.1:c.971-32A>G, XM_011511609.1:c.971-32A>G, rs60139689
A > G
SNP
No VIP available No Clinical Annotations available VA
rs2461817 NC_000003.11:g.119524651A>C, NC_000003.12:g.119805804A>C, NG_011856.1:g.30321A>C, NM_003889.3:c.-22-1425A>C, NM_022002.2:c.96-1425A>C, NM_033013.2:c.-22-1425A>C, XM_005247866.1:c.-187-1425A>C
A > C
SNP
No VIP available No Clinical Annotations available VA
rs2622628 NC_000004.11:g.89029252A>C, NC_000004.12:g.88108100A>C, NG_032067.2:g.128223T>G, NM_001257386.1:c.1195-834T>G, NM_004827.2:c.1195-834T>G, XM_005263354.1:c.1195-834T>G, XM_005263354.2:c.1195-834T>G, XM_005263355.1:c.1195-834T>G, XM_005263355.2:c.1195-834T>G, XM_005263356.1:c.1189-834T>G, XM_005263356.2:c.1189-834T>G, XM_011532420.1:c.1195-834T>G, rs386570725, rs59698865, rs61074534
A > C
SNP
No VIP available CA VA
rs28365063 NC_000004.11:g.69962610A>G, NC_000004.12:g.69096892A>G, NM_001074.2:c.372A>G, NP_001065.2:p.Arg124=, XM_005265702.1:c.-26-1648A>G, XM_005265702.2:c.-26-1648A>G, XM_011532229.1:c.372A>G, XM_011532230.1:c.372A>G, XM_011532231.1:c.-26-1648A>G, XP_011530531.1:p.Arg124=, XP_011530532.1:p.Arg124=, rs45568039, rs60754346
A > G
SNP
R124R
No VIP available CA VA
rs3114020 NC_000004.11:g.89083666T>C, NC_000004.12:g.88162514T>C, NG_032067.2:g.73809A>G, NM_001257386.1:c.-19-22500A>G, XM_005263355.1:c.-19-22500A>G, XM_005263355.2:c.-19-22500A>G, XM_011532420.1:c.-19-22500A>G, rs13137608
T > C
SNP
No VIP available No Clinical Annotations available VA
rs3212183
C > T
SNP
No VIP available No Clinical Annotations available VA
rs3812718 AB093548.1:c.603-91G>A, NC_000002.11:g.166909544C>T, NC_000002.12:g.166053034C>T, NG_011906.1:g.25606G>A, NM_001165963.1:c.603-91G>A, NM_001165964.1:c.603-91G>A, NM_001202435.1:c.603-91G>A, NM_006920.4:c.603-91G>A, XM_011511598.1:c.603-91G>A, XM_011511599.1:c.603-91G>A, XM_011511600.1:c.603-91G>A, XM_011511601.1:c.603-91G>A, XM_011511602.1:c.603-91G>A, XM_011511603.1:c.603-91G>A, XM_011511604.1:c.603-91G>A, XM_011511605.1:c.603-91G>A, XM_011511606.1:c.603-91G>A, XM_011511607.1:c.603-91G>A, XR_922981.1:n.787-91G>A, rs57229005
C > T
SNP
No VIP available No Clinical Annotations available VA
rs3814055 NC_000003.11:g.119500035C>T, NC_000003.12:g.119781188C>T, NG_011856.1:g.5705C>T, NM_003889.3:c.-1135C>T, NM_022002.2:c.-1570C>T, NM_033013.2:c.-1135C>T, XM_005247866.1:c.-1300C>T, rs60667929
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4828696 NC_000023.10:g.151581996T>C, NC_000023.11:g.152413524T>C, NG_007102.1:g.42835A>G, NM_000808.3:c.-27+37622A>G, XM_005274659.1:c.-27+37622A>G, XM_005274660.1:c.-27+37622A>G, XM_006724811.1:c.-27+37622A>G, XM_011531133.1:c.-27+37622A>G, XM_011531134.1:c.-27+37622A>G, rs56568387, rs60127194
T > C
SNP
No VIP available No Clinical Annotations available VA
rs511310 NC_000004.11:g.46240004A>G, NC_000004.12:g.46237987A>G, rs59093609
A > G
SNP
No VIP available No Clinical Annotations available VA
rs62298861 NC_000004.11:g.69963944A>G, NC_000004.12:g.69098226A>G, NM_001074.2:c.722-314A>G, XM_005265702.1:c.-26-314A>G, XM_005265702.2:c.-26-314A>G, XM_011532229.1:c.722-314A>G, XM_011532230.1:c.722-314A>G, XM_011532231.1:c.-26-314A>G
A > G
SNP
No VIP available CA VA
rs628031 NC_000006.11:g.160560845A>G, NC_000006.12:g.160139813A>G, NM_003057.2:c.1222A>G, NM_153187.1:c.1222A>G, NP_003048.1:p.Met408Val, NP_694857.1:p.Met408Val, XM_005267102.1:c.1222A>G, XM_005267102.3:c.1222A>G, XM_005267103.1:c.1222A>G, XM_005267104.1:c.646A>G, XM_005267104.3:c.646A>G, XM_005267105.1:c.646A>G, XM_005267105.3:c.646A>G, XM_006715552.1:c.1222A>G, XM_011536074.1:c.646A>G, XP_005267159.1:p.Met408Val, XP_005267160.1:p.Met408Val, XP_005267161.1:p.Met216Val, XP_005267162.1:p.Met216Val, XP_006715615.1:p.Met408Val, XP_011534376.1:p.Met216Val, rs1086277, rs17202481, rs60990824
A > G
SNP
M408V
No VIP available No Clinical Annotations available VA
rs6883877 NC_000005.10:g.161851332C>T, NC_000005.9:g.161278338C>T, NG_011548.1:g.9142C>T, NM_000806.5:c.74+448C>T, NM_001127643.1:c.74+448C>T, NM_001127644.1:c.74+448C>T, NM_001127645.1:c.74+448C>T, NM_001127648.1:c.74+448C>T, rs56705003
C > T
SNP
No VIP available No Clinical Annotations available VA
rs6892782 NC_000005.10:g.161842777T>C, NC_000005.9:g.161269783T>C, NG_011548.1:g.587T>C, rs56770940
T > C
SNP
No VIP available CA VA
rs7668258 NC_000004.11:g.69962078T>C, NC_000004.12:g.69096360T>C, NM_001074.2:c.-161T>C, XM_005265702.1:c.-26-2180T>C, XM_005265702.2:c.-26-2180T>C, XM_011532229.1:c.-161T>C, XM_011532230.1:c.-161T>C, XM_011532231.1:c.-26-2180T>C, rs17551675, rs60174701
T > C
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • GW 273293
  • Lamotrigina [Spanish]
  • Lamotriginum [Latin]
  • lamotrigine
Trade Names
  • Lamictal
  • Lamictal CD
  • Lamictal XR
  • Lamictin
Brand Mixture Names

PharmGKB Accession Id

PA450164

Type(s):

Drug

Description

Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. For epilepsy it is used to treat partial seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Lamotrigine also acts as a mood stabilizer. It is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. Chemically unrelated to other anticonvulsants, lamotrigine has relatively few side-effects and does not require blood monitoring. The exact way lamotrigine works is unknown. Wikipedia

Source: Drug Bank

Pharmacogenetics

Pharmacokinetics

The elimination of lamotrigine is mainly by hepatic metabolism to the glucuronide conjugate [Article:1773780]. UDP glucuronosyltransferase 1 family, polypeptide A4 (UGT1A4) was found to be involved in lamotrigine metabolism [Articles:11927765, 11593076]. Clearance of the drug is slightly lower in patients with Gilberts syndrome, who have decreased activity of uridine diphosphate glutamyl transferase [Article:1773780]. The degree of plasma protein binding is 56% [Article:8119045]. An in vitro study using a stable, recombinant P-glycoprotein (ABCB1) expression system found that ABCB1 haplotypes impacted the inhibitory effect of the drugs cyclosporin A, verapamil, phenytoin, carbamazepine, lamotrigine, phenobarbital, valproic acid, levetiracetam and gabapentin [Article:18408562].

Pharmacodynamics

Lamotrigine is a phenyltriazine compound and its mechanism of action is thought to stabilize neuronal membranes via blockade of voltage-sensitive sodium channels, which blocks the influx of sodium ions and thereby reduces excess glutamate release [Article:1350815].

Pharmacogenomics

A study in Chinese epilepsy patients investigated the association of the antiepileptic drugs phenytoin, carbamazepine, oxcarbazepine, lamotrigine, and topiramate responsiveness with genetic polymorphisms (SNPs) in neuronal sodium channels SCN1A, SCN2A, and SCN3A [Article:18784617]. Voltage-gated sodium channel type 2 alpha subunit (SCN2A) SNP rs2304016 A allele is associated with lamotrigine drug resistance [Article:18784617]. SNPs in the dopamine D2 receptor (DRD2), histamine H1 receptor (HRH1), dopamine beta-hydroxylase (DBH), glucocorticoid receptor (NR3C1), and melanocortin 2 receptor (MC2R) genes are significantly associated with response to lamotrigine in lamotrigine-treated white patients with bipolar I depression [Article:20021991]. Lamotrigine has the potential to produce idiosyncratic reactions and skin eruptions occur in about 3% of patients [Article:1350815]. Angiooedema and Stevens-Johnson syndrome have been reported [Article:1350815]. Several studies reported a high frequency of HLA-B*1502 in phenytoin- or lamotrigine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese patients [Articles:20235791, 17509004, 18637831, 20485159]. In patients with European origin no single major HLA-related genetic risk factor was identified for lamotrigine-induced severe cutaneous adverse reactions but suggestive evidence was obtained for B*5801, A*6801, Cw*0718, DQB1*0609, and DRB1*1301 [Article:19668019].

Source: PharmGKB

Indication

For the adjunctive treatment of partial seizures in epilepsy and generalized seizures of Lennox-Gastaut syndrome. Also for the maintenance treatment of bipolar I disorder and depression.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

One proposed mechanism of action of Lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. in vitro pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels and/or calcium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate). Studies on lamotrigine show binding to sodium channels similar to local anesthetics.

Source: Drug Bank

Pharmacology

Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is chemically unrelated to existing antiepileptic drugs. Lamotrigine is also used in the treatment of depression and bipolar disorder. Lamotrigine is thought to exert its anticonvulsant effect by stabilizing presynaptic neuronal membranes. Lamotrigine inhibits sodium currents by selectively binding to the inactivated state of the sodium channel and subsequently suppresses the release of the excilatory amino acid, glutamate.

Source: Drug Bank

Food Interaction

Take without regard to meals.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic

Source: Drug Bank

Protein Binding

55%

Source: Drug Bank

Absorption

98%

Source: Drug Bank

Half-Life

25 +/- 10 hours (healthy individuals); 42.9 hours (chronic renal failure)

Source: Drug Bank

Toxicity

LD 50=250 (mg/kg) (in rat, mice); LD 50>640 orally (mg/kg) (in rat, mice) (Sawyer). Symptoms of overdose include decreased level of consciousness, coma, delayed heartbeat, increased seizures, lack of coordination, and rolling eyeballs.

Source: Drug Bank

Volume of Distribution

  • 0.9 to 1.3 L/kg

Source: Drug Bank

Chemical Properties

Chemical Formula

C9H7Cl2N5

Source: Drug Bank

Isomeric SMILES

c1cc(c(c(c1)Cl)Cl)c2c(nc(nn2)N)N

Source: OpenEye

Canonical SMILES

NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1

Source: Drug Bank

Average Molecular Weight

256.091

Source: Drug Bank

Monoisotopic Molecular Weight

255.007850663

Source: Drug Bank

SMILES

NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1

Source: Drug Bank

InChI String

InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
DHFR (source: Drug Bank )
SCN1A (source: Drug Bank )
SCN2A (source: Drug Bank )
SCN3A (source: Drug Bank )
SCN4A (source: Drug Bank )
SCN5A (source: Drug Bank )
SCN8A (source: Drug Bank )
SCN9A (source: Drug Bank )

Drug Interactions

Interaction Description
carbamazepine - lamotrigine Decreases the effect of lamotrigine (source: Drug Bank )
carbamazepine - lamotrigine Decreases the effect of lamotrigine (source: Drug Bank )
clozapine - lamotrigine Lamotrigine increases the effect and toxicity of clozapine (source: Drug Bank )
clozapine - lamotrigine Lamotrigine increases the effect and toxicity of clozapine (source: Drug Bank )
divalproex sodium - lamotrigine Valproic acid increases the effect of lamotrigine (source: Drug Bank )
ethinyl estradiol - lamotrigine The oral contraceptive decreases the effect of lamotrigine (source: Drug Bank )
ethinyl estradiol - lamotrigine The oral contraceptive decreases the effect of lamotrigine (source: Drug Bank )
fosphenytoin - lamotrigine Phenytoin may reduce levels of lamotrigine (source: Drug Bank )
lamotrigine - carbamazepine Carbamazepine decreases the effect of lamotrigine (source: Drug Bank )
lamotrigine - carbamazepine Carbamazepine decreases the effect of lamotrigine (source: Drug Bank )
lamotrigine - clozapine Lamotrigine increases the effect and toxicity of clozapine (source: Drug Bank )
lamotrigine - clozapine Lamotrigine increases the effect and toxicity of clozapine (source: Drug Bank )
lamotrigine - desogestrel The oral contraceptive decreases the effect of lamotrigine (source: Drug Bank )
lamotrigine - desogestrel The oral contraceptive decreases the effect of lamotrigine (source: Drug Bank )
lamotrigine - estradiol The oral contraceptive decreases the effect of lamotrigine (source: Drug Bank )
lamotrigine - ethinyl estradiol The oral contraceptive decreases the effect of lamotrigine (source: Drug Bank )
lamotrigine - ethotoin Phenytoin may reduce levels of lamotrigine (source: Drug Bank )
lamotrigine - ethotoin Phenytoin may reduce levels of lamotrigine (source: Drug Bank )
lamotrigine - fosphenytoin Phenytoin may reduce levels of lamotrigine (source: Drug Bank )
lamotrigine - fosphenytoin Phenytoin may reduce levels of lamotrigine (source: Drug Bank )
lamotrigine - mephenytoin Phenytoin may reduce levels of lamotrigine (source: Drug Bank )
lamotrigine - mephenytoin Phenytoin may reduce levels of lamotrigine (source: Drug Bank )
lamotrigine - mestranol The oral contraceptive decreases the effect of lamotrigine (source: Drug Bank )
lamotrigine - mestranol The oral contraceptive decreases the effect of lamotrigine (source: Drug Bank )
lamotrigine - methsuximide Methsuximide decreases the effect of lamotrigine (source: Drug Bank )
lamotrigine - methsuximide Methsuximide decreases the effect of lamotrigine (source: Drug Bank )
lamotrigine - norethindrone The oral contraceptive decreases the effect of lamotrigine (source: Drug Bank )
lamotrigine - norethindrone The oral contraceptive decreases the effect of lamotrigine (source: Drug Bank )
lamotrigine - phenytoin Phenytoin may reduce levels of lamotrigine (source: Drug Bank )
lamotrigine - phenytoin Phenytoin may reduce levels of lamotrigine (source: Drug Bank )
lamotrigine - rifampin Rifampin decreases levels of lamotrigine (source: Drug Bank )
lamotrigine - rifampin Rifampin decreases levels of lamotrigine (source: Drug Bank )
lamotrigine - sodium Valproic acid increases the effect of lamotrigine (source: Drug Bank )
lamotrigine - sodium Valproic acid increases the effect of lamotrigine (source: Drug Bank )
norethindrone - lamotrigine The oral contraceptive decreases the effect of lamotrigine (source: Drug Bank )
norethindrone - lamotrigine The oral contraceptive decreases the effect of lamotrigine (source: Drug Bank )
phenytoin - lamotrigine Phenytoin may reduce levels of lamotrigine (source: Drug Bank )
phenytoin - lamotrigine Phenytoin may reduce levels of lamotrigine (source: Drug Bank )
rifampin - lamotrigine Rifampin decreases levels of lamotrigine (source: Drug Bank )
rifampin - lamotrigine Rifampin decreases levels of lamotrigine (source: Drug Bank )
thiopental - lamotrigine Thiopental may increase the metabolism and clearance of Lamotrigine. Monitor for decreased therapeutic effect of Lamotrigine if Thiopental is initiated. (source: Drug Bank )
thiopental - lamotrigine Thiopental may increase the metabolism and clearance of Lamotrigine. Monitor for decreased therapeutic effect of Lamotrigine if Thiopental is initiated. (source: Drug Bank )
triprolidine - lamotrigine The CNS depressants, Triprolidine and Lamotrigine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank )
triprolidine - lamotrigine The CNS depressants, Triprolidine and Lamotrigine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank )
valproic acid - lamotrigine Valproic acid may increase the adverse effects of Lamotrigine by increasing Lamotrigine serum concentration. The Lamotrigine dose should be reduced by 50% during concomitant therapy. Monitor for changes in Lamotrigine therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed. (source: Drug Bank )

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to lamotrigine: 40

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. Epilepsy research. 2016. Shen Chun-Hong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. British journal of clinical pharmacology. 2016. Milosheska Daniela, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy. European journal of clinical pharmacology. 2016. Inoue Kazuyuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs. Yonsei medical journal. 2016. Park Hye Jung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction. Pharmacogenomics. 2015. Rufini Sara, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms of ABCG2, ABCB1 and HNF4alpha are associated with Lamotrigine trough concentrations in epilepsy patients. Drug metabolism and pharmacokinetics. 2015. Zhou Yafang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between HLA-B*15:02 allele and antiepileptic drug-induced severe cutaneous reactions in Hong Kong Chinese: a population-based study. Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine. 2014. Kwan P K L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of HLA-B*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis. International journal of dermatology. 2014. Zeng Tao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
T Cell-Mediated Hypersensitivity Reactions to Drugs. Annual review of medicine. 2014. Pavlos Rebecca, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Clinical features of and genetic predisposition to drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients-investigating the relation between the HLA -B*4403 allele and lamotrigine. European journal of clinical pharmacology. 2014. Park Hye Jung, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China. European journal of clinical pharmacology. 2014. Chang Ying, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics. 2014. Ma Chun-Lai, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of antiepileptic drug-induced hypersensitivity. Pharmacogenomics. 2014. Bloch Katarzyna M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients. Pharmacogenomics. 2014. Fricke-Galindo Ingrid, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene-wide tagging study of the effects of common genetic polymorphisms in the alpha subunits of the GABAA receptor on epilepsy treatment response. Pharmacogenomics. 2013. Hung Chin-Chuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese. Epilepsy research. 2013. Li Li-Juan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013. Cheung Ying-Kit, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. European journal of clinical pharmacology. 2013. Singkham Noppaket, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Lamotrigine-induced hypersensitivity syndrome in a Han Chinese patient with the HLA-B 5801 genotype. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2013. Chow Julie Chi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics. 2012. McCormack Mark, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lack of association between ABCC2 gene variants and treatment response in epilepsy. Pharmacogenomics. 2012. Hilger Eva, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes. Pharmacogenomics. 2011. Zhou Jin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. Basic & clinical pharmacology & toxicology. 2011. Shi Yi-Wu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. Epilepsia. 2011. Thompson Christopher H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics. 2011. Kwan Patrick, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association study of serious blistering skin rash caused by drugs. The pharmacogenomics journal. 2011. Shen Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population. Epilepsy research. 2010. An Dong-Mei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics. 2010. Becker Mara L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches. Pharmacogenomics. 2010. Potschka Heidrun. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010. Hung Shuen-Iu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Key factors in the discovery and development of new antiepileptic drugs. Nature reviews. Drug discovery. 2010. Bialer Meir, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenetics and genomics. 2009. Kazeem Gbenga R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. Pharmacogenomics. 2009. Kwan Patrick, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenetics and genomics. 2008. Kwan Patrick, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenetics and genomics. 2008. Hung Chin-Chuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenetics and genomics. 2008. Lonjou Christine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. The Journal of investigative dermatology. 2008. Mockenhaupt Maja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Defining the clinical role of pharmacogenetics in antiepileptic drug therapy. The pharmacogenomics journal. 2006. Dlugos D J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0173-0633-02
DrugBank:
DB00555
ChEBI:
6367
KEGG Drug:
D00354
PubChem Compound:
3878
PubChem Substance:
46505408
7847420
IUPHAR Ligand:
2622
Drugs Product Database (DPD):
2248232
BindingDB:
50031299
ChemSpider:
3741
Therapeutic Targets Database:
DAP000039
FDA Drug Label at DailyMed:
d7e3572d-56fe-4727-2bb4-013ccca22678

Clinical Trials

These are trials that mention lamotrigine and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.